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Summary
The role of Ras oncogenes in promoting cellular transformation is well established. However, the contribution of Ras
signaling to interactions between tumor cells and their host environment remains poorly characterized. Here, we demon-
strate that the inflammatory mediator interleukin-8 (CXCL-8/IL-8) is a transcriptional target of Ras signaling. Using a
tumor xenograft model, we show that Ras-dependent CXCL-8 secretion is required for the initiation of tumor-associated
inflammation and neovascularization. Collectively, our data identify a novel mechanism by which the Ras oncogene can
elicit a stromal response that fosters cancer progression.
Introduction proliferative signals is performed by the Ras effector Raf-kinase,
which activates the ERK-MAP-kinase cascade (Downward,
1997). ERK, in turn, phosphorylates and activates transcriptionTumor development is driven by the sequential acquisition of
genetic alterations involving the constitutive activation of pro- factors, thereby inducing cell cycle regulatory genes required
for entry into S phase of the cell cycle (Marais et al., 1993; Gilletooncogenes and the loss of function of tumor suppressor
genes. These changes confer a specific set of cellular traits that et al., 1995). The initiation of survival signals, on the other hand,
is primarily mediated by the interaction of Ras with the catalyticrelease cells from their normal growth constraints. Although
many tumor characteristics can be attributed to the genetically subunit of phosphoinositol 3-kinase (PI3K) (Kauffmann-Zeh et
al., 1997). This interaction leads to the activation of the serine/altered cell itself, it is becoming increasingly clear that the ability
of malignant cells to interact with and influence their tissue threonine kinase Akt/PKB, which in turn augments cell survival
by suppressing or enhancing pro- or antiapoptotic functions,environment is critical for cancer development. For example,
during tumor progression, cancer cells activate stromal fibro- respectively (Brazil et al., 2004). In addition, Ras signaling con-
tributes to the metastatic properties of tumor cells through theblasts and recruit inflammatory cells, which remodel the tumor
stroma in part through the secretion of proteases (Coussens et activation of effector pathways involving Rho GTPases. Activa-
tion of these GTPases promotes cell motility by inducing specifical., 1999; Lin et al., 2001; Liotta and Kohn, 2001). This, in turn,
leads to the release of growth-promoting factors sequestered changes in the organization of the actin cytoskeleton (Schmitz
et al., 2000).in the extracellular matrix (ECM) and liberates neoplastic cells
from the constraints of contact inhibition (MacDougall and Matri- Apart from these cell-autonomous effects, Ras oncogene
expression promotes and sustains tumor-host interactions thatsian, 1995; Egeblad and Werb, 2002). In addition, tumor-associ-
ated inflammation also appears to play a key role in the initiation are essential for neoplastic development. Constitutive Ras activ-
ity has been shown to contribute to increased tumor cell inva-of angiogenesis as suggested by the findings that infiltration of
mast cells at the tumor site activates premalignant neovasculari- siveness through the activation of matrix metalloproteinases,
which initiate basement membrane degradation (Ballin et al.,zation (Coussens et al., 1999).
About 25% of all human neoplasms contain mutationally 1988). Furthermore, Ras is known to promote endothelial cell-
dependent tumor angiogenesis, mainly by means of transcrip-activated forms of the Ras protooncogene (Bos, 1989). Ras
proteins exert their tumorigenic effects through the activation of tional upregulation of vascular endothelial growth factor (VEGF)
and through the repression of the antiangiogenic protein throm-an intricate signaling network consisting of multiple downstream
effectors (Campbell et al., 1998). A central role in transmitting bospondin-1 (TSP-1) (Okada et al., 1998; Rak et al., 2000; Wat-
S I G N I F I C A N C E
The instructive interactions between tumor cells and their microenvironment are now recognized as essential determinants in the
development of malignancy. In particular, the recruitment of blood vessels to the tumor site is a prerequisite of tumor growth and
metastasis. In the present study, we show that the transcriptional upregulation of the chemokine interleukin-8 (CXCL-8/IL-8) by
oncogenic Ras is required for the onset of tumor vascularization. Our findings underscore the contribution of dysregulated CXCL-8
expression to the process of Ras-mediated tumorigenesis and suggest that this chemokine and its receptors may serve as attractive
anticancer therapeutic targets.
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Figure 1. Expression of H-RasV12 induces CXCL-8 transcription and protein synthesis
HeLa Tet-Off H-RasV12 transgenic cells (HTO H-RasV12) were cultured with the indicated concentrations of doxycycline 24 hr prior to lysis.
A: Total cell extracts were used to detect both exogenous and endogenous Ras protein by Western blot analysis.
B: RNA was isolated and subjected to RT-PCR analysis using specific primers to the indicated genes.
C: Tissue culture supernatants were analyzed by human CXCL-8-specific ELISA. Results are reported as the mean  SD of three independent experiments
each run in duplicate.
nick et al., 2003). However, the signaling mechanisms that medi- Figure 2, H-RasV12 increased CXCL-8 expression in both a
lung carcinoma cell line (H125) and a normal, spontaneouslyate the effects of Ras on the interactions between tumor cells
immortalized human lumenal mammary epithelial cell line (MCF-and their host environment remain poorly understood.
10A). The mammalian genome encodes four Ras isoforms,In the current study, we have analyzed the functional signifi-
which, despite their high homology, appear to possess uniquecance of Ras-mediated induction of the proinflammatory che-
signaling properties and different oncogenic potential (Bos,mokine interleukin-8 (CXCL-8/IL-8). Using a nude mouse xeno-
1989; Bar-Sagi, 2001). To determine whether the ability to in-graft model, we demonstrate that CXCL-8 synthesis and
duce CXCL-8 expression reflects a unique property of H-Ras,secretion is required for RasV12-stimulated tumor inflammation,
we infected cells with an adenoviral construct that directs thevascularization, and growth. These observations suggest a
expression of constitutively active K-Ras. Similar to H-Ras, sig-
novel signaling mechanism by which neoplastic cells can trigger
naling from the K-Ras isoform led to an increase in both CXCL-8
angiogenesis through the recruitment of immune cells to tumor mRNA and protein (Figure 2). It is noteworthy that the levels
sites. of CXCL-8 expression varied between the different cell types.
Presumably, these differences are dictated by cellular context,
Results as the infection efficiencies were similar for each of the various
cell lines (Supplemental Figure S1 at http://www.cancercell.org/
Induction of interleukin-8 by RasV12 cgi/content/full/6/4/447/DC1/). Overall, these results indicate
To identify Ras target genes, we performed high-density oligo- that the signaling pathways leading from Ras to CXCL-8 upregu-
lation are functional in both tumor-derived and normal humannucleotide-based microarray analyses in HeLa cell lines ex-
cells and conserved between at least two Ras isoforms.pressing activated H-RasG12→V transgenes under a tetracy-
cline responsive promoter (Tet-Off Expression System). Among
Ras-mediated transcriptional upregulation of CXCL-8all targets represented on the Affymetrix GeneChip, mRNA tran-
requires the concurrent activation of both MAPKscripts of interleukin-8 (CXCL-8/IL-8), a well-characterized pro-
and PI3K effector pathwaysinflammatory chemokine, exhibited the most substantial (63-
The induction of CXCL-8 message coincided with H-RasV12fold) upregulation in response to H-RasV12 expression. This
protein expression, suggesting an immediate effect of Ras-observation is in agreement with a recent study, in which RasV12
mediated signaling on CXCL-8 transcription (Supplemental Fig-expression in human ovarian cells was shown to induce various
ure S2 at http://www.cancercell.org/cgi/content/full/6/4/447/cytokines involved in inflammatory responses, including CXCL-8
DC1/). To analyze the role of different Ras effector pathways in
(Liu et al., 2004).
CXCL-8 transcription, we utilized a reporter construct in which
To validate the results from the global gene expression anal- the minimal CXCL-8 promoter region was fused to the firefly
ysis, we examined the induction of CXCL-8 by RT-PCR and luciferase gene (Wu et al., 1997). Constitutive activation of the
ELISA. A significant increase in CXCL-8 mRNA and protein ERK cascade through a dominant active mutant of Raf, Raf-
levels (Figures 1B and 1C) was observed in response to both CAAX, or of the PI3K pathway through the membrane-targeted
near-physiological and supraphysiological levels of H-RasV12 catalytic subunit of PI3K, p110CAAX, led to partial activation
(Figure 1A). To exclude cell type-specific effects of Ras on of the CXCL-8 promoter (Figure 3A). However, simultaneous
CXCL-8 expression, we have analyzed the induction of CXCL-8 activation of both pathways through the coexpression of Raf-
by H-RasV12 signaling in two additional human cell lines of CAAX and p110CAAX increased luciferase activity to the levels
reached by H-RasV12 expression. This indicates that maximalepithelial origin using adenoviral gene delivery. As illustrated in
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Figure 2. RasV12-induced CXCL-8 expression in different human cell lines
Cervical cancer cells (HeLa), lung carcinoma cells (H125), and normal breast epithelial cells (MCF10A) were infected with recombinant adenovirus that
directs the expression of either -galactosidase (Ad--Gal), HA-epitope-tagged H-RasV12 (Ad-HRasV12), or K-RasV12 (Ad-KRasV12) as indicated. All samples
were harvested 24 hr after infection.
A: Cytoplasmic lysates were used to detect expression of the HA-RasV12 transgenes with an antibody raised against the HA-epitope tag.
B: RNA was isolated and subjected to RT-PCR using CXCL-8-specific primers.
C: Tissue culture supernatants were analyzed by human CXCL-8-specific ELISA analysis. Results are reported as the mean  SD of three independent
experiments, each run in duplicate.
induction of CXCL-8 gene expression depends on the concur- dependent mechanisms (Welch et al., 2003). To differentiate
between the contributions of Akt or Rac to the activation ofrent activation of both Ras effector pathways. The contributions
of these signaling cascades to Ras-mediated CXCL-8 induction CXCL-8 transcription, we attempted to mimic PI3K signaling by
expressing either a mutant of Akt that is rendered constitutivelywere further confirmed by demonstrating that the pharmacologi-
cal inhibitors U0126 and LY294002, which specifically target active through a myristoylation sequence at its carboxy-termi-
nus (myrAkt), or a dominant active mutant of Rac, RacV12.the ERK-MAPK and the PI3K pathway, respectively, abrogated
CXCL-8 induction by H-RasV12 (Figure 3B). Expression of either myrAkt or RacV12 led to a moderate in-
crease in luciferase activity (Figure 3A). To ascertain that inWe next sought to dissect the pathways downstream of
PI3K involved in the induction of CXCL-8. A central role in PI3K- our experimental system, Rac signals downstream of PI3K, we
coexpressed a dominant interfering mutant of Rac, RacN17,mediated signaling is performed by the serine/threonine kinase
Akt/PKB (Franke et al., 1997). Additionally, there is growing together with p110CAAX. RacN17 partially inhibited PI3K-
induced CXCL-8 promoter activity, indicating the involvementevidence that the small GTPase Rac is regulated by PI3K-
Figure 3. Analysis of transcriptional regulation of the CXCL-8 promoter by RasV12 signaling in HeLa cells
A: HeLa cells were cotransfected with a CXCL-8-luciferase reporter construct and the indicated expression plasmids. Luciferase assays were conducted
24 hr after transfection. Results are reported as the mean  SD of three independent experiments performed in triplicate and normalized for transfection
efficiency using -galactosidase.
B: Tissue culture supernatants from HTO H-RasV12 cells cultured in the presence () or absence () of 1 ng/ml doxycycline for 16 hr were collected and
analyzed using CXCL-8-specific ELISA. Selective inhibitors of MEK (U0126) and PI3K (LY 294002) were added at the indicated concentrations at the time of
induction. Values represent the mean  SD of three independent experiments performed in duplicate.
C: Schematic diagram of the signaling pathways mediating Ras-induced transcriptional upregulation of CXCL-8.
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of Rac in the induction of CXCL-8 by PI3K (Figure 3A). Akt and injections at the tumor site were initiated two days after tumor
cell inoculation, at which point palpable nodules had developed,Rac both stimulate the transcription factor nuclear factor B
(NFB) (Perona et al., 1997; Romashkova and Makarov, 1999). and were thereafter continued twice a week. The efficiency of
CXCL-8 targeting by this protocol is indicated by the absenceSince NFB is an established activator of the CXCL-8 promoter
(Matsusaka et al., 1993), we aimed to determine whether the of detectable CXCL-8 levels in the serum of animals injected
with the CXCL-8 neutralizing antibody at every stage of tumoreffects of Akt and Rac on CXCL-8 promoter activity are medi-
ated through this transcription factor. To this end, we coex- development (Supplemental Figure S3). Whereas no significant
differences were observed between tumor size from isotype-pressed myrAkt or RacV12 with a dominant interfering mutant
of the NFB cascade, the inhibitor of NFB (IB) super-repressor matched (IgG1) control antibody treated and untreated groups,
animals injected with the CXCL-8 neutralizing antibody demon-protein, which is a nondegradable form of IB that binds to
NFB and prevents its translocation into the nucleus (Brockman strated an approximate 60% reduction in tumor growth rate at
the time of sacrifice when compared with animals bearing con-et al., 1995). Only myrAkt-mediated induction of luciferase activ-
ity could be inhibited by the IB super-repressor, indicating that trol injected or noninjected tumors (Figures 4B and 4C). We
confirmed that injection of either antibody did not interfere withAkt acts upstream of NFB to induce CXCL-8 transcription,
while RacV12 activates the CXCL-8 promoter through an alter- H-RasV12 expression as demonstrated by transgene-specific
immunoblot analysis of tumor lysates (Figure 4D).native pathway (Figure 3A). One additional mechanism mediat-
ing the effects of Rac on transcription is the activation of the To rule out the possibility that the effects of MAB208 are due
to nonspecific in vivo crossreactivity, we employed a differentc-Jun N-terminal (JNK) kinase cascade (Coso et al., 1995). Ex-
pressing a construct in which JNK is rendered constitutively CXCL-8 antibody, I8-6 (Antigenix America). Like MAB208, this
antibody has potent CXCL-8 neutralizing activity as judged byactive through a fusion to the activation domain of MKK-7 (Lei
et al., 2002) led to partial activation of the CXCL-8 promoter, a neutrophil chemotaxis assay (Supplemental Figure S4 at
http://www.cancercell.org/cgi/content/full/6/4/447/DC1/).suggesting that activation of JNK might play a role in the induc-
tion of CXCL-8 transcription (Figure 3A). That Rac and NFB Significantly, introduction of I8-6 into H-RasV12 expressing tu-
mors through the same injection regimen used for MAB208are necessary for Ras-induced CXCL-8 expression was further
established by the finding that either RacN17 or the IB super- inhibited Ras-induced tumor growth (Supplemental Figure S4).
Together, these observations indicate that interference withrepressor protein inhibited H-RasV12 induced activation of the
CXCL-8 promoter (Figure 3A). CXCL-8 function curtails the tumorigenic potential of H-RasV12.
In all subsequent analyses, tumors injected with IgG1 antibody
were indistinguishable from noninjected tumors and were there-Neutralization of CXCL-8 in RasV12-expressing
subcutaneous tumors attenuates fore used as a control for tumors injected with the CXCL-8
neutralizing antibody.neoplastic growth
We next sought to determine whether the induction and secre-
tion of CXCL-8 in response to RasV12 signaling contributes CXCL-8 functions in a non-cell-autonomous manner
In principle, the effect of CXCL-8 could be mediated by autocrineto Ras-mediated tumorigenesis. To this end, we conducted
xenograft studies using immunocompromised nude mice. Ani- and/or paracrine mechanisms. FACS analysis of the expression
of the two CXCL-8 receptors CXCR-1 and -2 in H-RasV12-mals were divided into two experimental groups. The first cohort
was injected subcutaneously with H-RasV12 transgenic HTO expressing HTO cells demonstrated that these cells did not
express significant levels of either CXCL-8 receptor (Figure 5A).cells cultured in the presence of doxycycline to repress expres-
sion of H-RasV12. In vivo suppression of H-RasV12 transcription Moreover, neither receptor was expressed in the course of tu-
mor development, as determined by RT-PCR analysis of humanin these cells was maintained by supplementing the drinking
water with 2 mg/ml doxycycline. The second cohort received CXCR-1 and -2 in neoplastic tissue isolated at different time
points after tumor cell inoculation (Figure 5B). These resultsHTO H-RasV12 cells induced to express H-RasV12 through
removal of doxycyline 24 hr prior to introduction into the host. argue against CXCL-8 functioning in an autocrine fashion in our
experimental system. This interpretation is further supported byThe regulation of H-RasV12 transgene expression in vivo was
confirmed by immunoblot analysis of tumor lysates (data not the observation that CXCL-8 did not exhibit a growth-stimula-
tory effect on HTO cells maintained either in growth factor-shown). Animals were monitored for subcutaneous tumor for-
mation and the growth rate of the developing tumors was estab- poor medium (0.5% serum) or in serum-containing medium (5%
serum) (Figure 5C). Additionally, the migratory behavior of HTOlished. As illustrated in Figure 4A, H-RasV12 expression signifi-
cantly enhanced tumor growth in experimental animals. ELISA cells was not influenced by the addition of CXCL-8, as measured
by a modified Boyden chamber assay (Supplemental Figureanalysis of serum taken from experimental animals at different
time points after tumor cell inoculation revealed the presence S5). Collectively, these findings suggest that the role of CXCL-8
of CXCL-8 in the bloodstream of mice injected with H-RasV12- in tumor growth is mediated through nonautonomous effects
expressing cells at levels that appear to correlate with tumor on stromal cells.
size (Supplemental Figure S3 at http://www.cancercell.org/cgi/
content/full/6/4/447/DC1/). Inhibition of CXCL-8 function does not affect tumor cell
proliferation, but leads to an increase in tumor cell deathTo investigate the contributions of CXCL-8 to H-RasV12-
induced tumor growth, we inhibited CXCL-8 function using a and an impairment of tumor vascularization
To analyze the mechanisms underlying the requirement ofCXCL-8 neutralizing antibody, MAB208 (R&D Systems). This
approach has been applied successfully to document the role CXCL-8 for Ras-induced tumor growth, we have examined
whether CXCL-8 neutralization alters the proliferative status ofof CXCL-8 in proliferation and subcutaneous growth of Kaposi’s
sarcoma-derived tumor cells (Masood et al., 2001). Antibody H-RasV12-expressing tumor cells. End-stage tumors excised
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Figure 4. Inhibition of CXCL-8 activity in vivo attenuates RasV12-induced tumor growth
A: HTO H-RasV12 cells were cultured in the presence (uninduced) or absence (H-RasV12) of doxycycline for 24 hr and then subcutaneously injected into
immunocompromised nude mice. The graphs indicate the mean tumor growth rates  SD of three animals per experimental condition.
B: Nude mice were inoculated with HTO H-RasV12 cells, either repressed for transgene expression (uninduced) or expressing H-RasV12 (H-RasV12). Animals
receiving H-RasV12-expressing HTO cells were randomized into three groups and either not injected or injected at the tumor site with 100 g IgG1 control
antibody (IgG) or 100 g neutralizing antibody to CXCL-8 (MAB208) on days 2, 6, 9, 13, and 16 after tumor cell inoculation. The graphs indicate the mean
tumor growth rates  SD of six animals per experimental condition (*p  0.05; **p  0.01).
C: Tumors were excised from animals at day 18 after tumor cell inoculation when the largest tumor had reached a diameter of 2 cm. Representative
examples for each experimental group are shown.
D: Tumor tissue was lysed and HA-RasV12 protein was detected by immunoblot analysis using an antibody against the epitope-tag.
from the animals at day 18 postinoculation were immunostained vessel number and diameter (Figure 6C). This analysis revealed
a significant enhancement of vascularization in H-RasV12-for proliferating cell nuclear antigen (PCNA), a marker for cycling
cells. H-RasV12-expressing tumors that were injected with the expressing tumors injected with the IgG1 control antibody as
compared to the stunted vasculature found in uninduced tu-IgG1 control antibody demonstrated an enhanced proliferative
index (62 8%) when compared to nonexpressing tumors (20 mors. Injection of H-RasV12-expressing tumors with MAB208
drastically reduced the increase in vascular density induced11%). Injection with the CXCL-8 interfering antibody did not
have a significant effect on the mitogenic rate of H-RasV12- by H-RasV12 (Figure 6C). Since the two major determinants
implicated thus far in Ras-induced angiogenesis, VEGF upregu-expressing tumors (58  10%) (Figure 6A). Thus, inhibition of
tumor growth as a consequence of CXCL-8 inactivation cannot lation and thrombospondin-1 suppression (Okada et al., 1998;
Rak et al., 2000; Watnick et al., 2003), are not affected bybe attributed to a decrease in neoplastic cell proliferation.
In contrast, inhibition of CXCL-8 had a pronounced effect MAB208 injection (Figure 6D), we conclude that CXCL-8 func-
on tumor cell necrosis. Microscopic examination of H-RasV12- tion is specifically required for Ras-induced tumor vasculari-
expressing tumors injected with CXCL-8 neutralizing antibody zation.
revealed areas of extensive necrosis, comprising 66% of total
tumor area (Figure 6B). Necrosis was characterized by the pres- CXCL-8-dependent recruitment of endothelial cells
early in tumor development occurs coincidentence of fragmented nuclear and cytoplasmic debris and a nearly
complete lack of intact cells (Figure 6B, inset). In contrast, with stromal infiltration of inflammatory cells
To investigate whether CXCL-8 plays a role in the induction ofH-RasV12 expressing tumors injected with the isotype control
antibody formed solid masses that had only sparse patches of angiogenesis during early stages of tumor development, we
analyzed neoplastic tissue five days after cell inoculation, theless advanced necrosis encompassing approximately 30% of
tumor area (Figure 6B). earliest time point at which tumors reached a size that permitted
their excision from the animals. Immunohistochemical stainingWe speculated that this substantial increase in tissue necro-
sis observed after ablation of CXCL-8 function was attributable with an antibody against the endothelial cell marker CD31 dem-
onstrated the presence of CD-31-positive cells in H-RasV12-to an impairment of angiogenesis, with tumor cell death oc-
curring in response to hypoxic stress. To address this question, expressing tumors injected with the IgG1 control antibody (Fig-
ure 7A). In contrast, endothelial cells were absent in MAB208tumor tissue was evaluated histochemically using CD31 staining
for tumor-associated vessels and quantitatively assessed for injected tumors, indicating that H-RasV12-induced CXCL-8 is
CANCER CELL : NOVEMBER 2004 451
A R T I C L E
Figure 5. CXCL-8 does not function as an autocrine factor for HTO cells
A: H-RasV12-expressing HTO cells were assessed for CXCR-1 (light gray profile) or CXCR-2 (dark gray profile) expression by FACS analysis. Human polymorpho-
nuclear neutrophils (PMN) served as positive control. Filled profiles show the labeling with isotype-matched IgG control antibody.
B: RNA was isolated from two independent tumors excised at day 5, 12, or 18 after tumor cell inoculation and subjected to RT-PCR analysis using specific
primers to the indicated genes. Human PMN served as control.
C: HTO H-RasV12 cells were grown in the presence of 1 ng/ml doxycycline under the indicated conditions. Cell numbers were counted every 24 hr. Values
shown represent the mean and standard deviation of three replicate experiments.
essential for the recruitment of endothelial cells to the tumor sinophils and has been shown to lead to the effective depletion
of these cell types in vivo (Sitia et al., 2002). As illustrated insite (Figure 7A).
Because inflammation has been implicated in the initiation Figures 7C and 7D, the injection of RB6-8C5 resulted in a sig-
nificant attenuation of tumor inflammation and endothelial cellof tumor vascularization (Bergers et al., 2000), we investigated
whether the recruitment of endothelial cells in H-RasV12- recruitment. Thus, the inflammatory response induced by
CXCL-8 expression is required for the neovascularization ofexpressing tumors is linked to the presence of inflammatory
cells. Immunohistochemical analysis using an antibody directed H-RasV12-expressing tumors.
against M-integrin (MAC/CD11b) revealed infiltration of macro-
phages and granulocytes at the core of early-stage H-RasV12- Discussion
expressing tumors injected with IgG1 control antibody (Figure
7B). Notably, the recruitment of these types of cells has been In the present study, we have characterized the functional sig-
nificance of the upregulation of interleukin-8 (CXCL-8/IL-8) byshown to precede the activation of premalignant neovasculari-
zation (Coussens et al., 1999). Ablation of CXCL-8 function oncogenic Ras. CXCL-8 induction is necessary for RasV12-
induced tumor growth, and ablation of CXCL-8 function inthrough injection of the CXCL-8 neutralizing antibody into
H-RasV12-expressing tumors significantly reduced infiltration RasV12-expressing tumors leads to a substantial decrease in
tumor vasculature and extensive tissue necrosis. These findingsby inflammatory cells (Figure 7B), but had no effect on tumor
cell proliferation (data not shown). These results demonstrate indicate a role for CXCL-8 in Ras oncogene-dependent tumor
angiogenesis.that early-stage H-RasV12-expressing tumors are dependent
on CXCL-8 production for both the mobilization of endothelial CXCL-8 expression is induced by a wide variety of stimuli,
including proinflammatory cytokines such as interleukin-1 orcells and the development of an inflammatory response.
To further examine the cause-and-effect relationship be- tumor necrosis factor, bacterial and viral products, and cellular
stress. The transcriptional events necessary for the induction oftween CXCL-8-induced inflammation and angiogenesis in
H-RasV12-expressing tumors, experimental animals were sub- CXCL-8 promoter activity have been extensively characterized
(Hoffmann et al., 2002). In particular, the transcription factorsjected to i.p. injection of a monoclonal antibody directed against
the myeloid differentiation antigen Gr-1/Ly-6-G (RB6-8C5, BD AP-1 and NFB have been shown to play a central role in the
modulation of CXCL-8 expression (Yasumoto et al., 1992). BothBiosciences). This antibody is cytotoxic for neutrophils and eo-
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Figure 6. Inhibition of CXCL-8 function does not affect tumor cell proliferation, but leads to an increase in tumor cell death and an impairment of tumor
vascularization
A: Uninduced or H-RasV12-expressing neoplastic tissues excised at day 18 from mice injected with control IgG1 antibody or MAB208 as indicated were
immunohistochemically stained using an antibody to PCNA. Representative examples of tumor sections stained with PCNA are shown in the photomicro-
graphs. Scale bar represents 20 m. Results are shown as the percentages of PCNA positive cells in six high magnification fields per section. Each data
point is derived from six tumors and corresponds to the mean  SD (*p  0.05; **p  0.01).
B: Fixed sections of RasV12-expressing tumors excised at day 18 from mice injected with the IgG1 control antibody or MAB208 were stained with H&E.
Necrotic areas are marked with dashed lines. V denotes areas of viable tumor cells, N denotes areas of necrosis. Scale bar represents 200 m. Insets are
higher magnification (40	) images. Scale bar in insets corresponds to 20 m. The surface area of necrotic tissue relative to the total surface area of the
field of view was quantified by morphometric analysis. Values are the averages from six independent tumors per experimental condition. Standard deviations
are indicated by error bars (**p  0.01).
C: Sections of uninduced tumors, RasV12-expressing tumor injected with IgG1 control antibody, or RasV12-expressing tumors injected with MAB208 were
stained using an antibody against the endothelial cell surface marker CD31. Scale bar represents 50 m. Blood vessel density and diameter was quantified
by morphometric analysis. Values are the averages from six independent tumors per experimental condition. Standard deviations are indicated by error
bars (**p  0.01; ***p  0.001).
D: RNA isolated from tumors excised at day 18 after tumor cell inoculation was subjected to RT-PCR analysis using primers to the indicated genes. The two
distinct bands amplified by VEGF-specific primers represent splice variants of the VEGF-A gene. For each experimental condition, the two lanes represent
two independent tumors.
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Figure 7. Endothelial cell recruitment during early
stages of tumor growth correlates with infiltration
of macrophages and granulocytes at the tumor
site
Neoplastic tissue excised at day five after tumor
cell inoculation from animals injected with IgG
control antibody, MAB208 (A and B) or RB6-
8C5 (C and D) was stained with an antibody
directed against the endothelial cell marker
CD31 or M-integrin (MAC/CD11b). Photomi-
crographs show representative examples of
three independent tumors analyzed per experi-
mental condition. Scale bar represents 50 m.
Results are shown as the number of stained cells/
field counting six high magnification fields per
section. Each data point is derived from three
independent tumors and corresponds to the
mean  SD (*p  0.05;**p  0.01).
of these transcriptional regulators are well-known targets of Ras Ras-dependent VEGF induction can be significantly influenced
signaling, and it has been shown that the integrity of the Ras by physiological and environmental effects, such as high cell
pathway is required for ligand-mediated CXCL-8 expression density and hypoxia (Mazure et al., 1996; Rak et al., 2000). VEGF
(Zhao et al., 2001). We have established that oncogenic activa- has been shown to play an essential role in tumor angiogenesis
tion of Ras is sufficient to induce a pronounced increase in meditated by Ras (Shi and Ferrara, 1999). However, under some
CXCL-8 expression. This effect is mediated by the coordinated circumstances, the upregulation of VEGF by Ras is clearly not
activation of several Ras effector pathways, thus offering multi- sufficient for progressive tumor growth, as indicated by the
ple potential targets for therapeutic intervention. inability of ectopically expressed VEGF to recapitulate the pro-
It is widely accepted that the growth of solid tumors beyond angiogenic effects of oncogenic Ras (Chin et al., 1999; Okada
microscopic sizes is dependent on the development of an intact
et al., 1998). An additional mechanism by which Ras signaling
tumor vasculature. Among several growth factors that can func-
might promote angiogenesis is through the repression of thetion as positive regulators of angiogenesis, vascular endothelial
antiangiogenic protein thrombospondin-1 (TSP-1) (Rak et al.,growth factor (VEGF) is thought to play a central role by promot-
2000). This notion is supported by the recent demonstrationing the proliferation, survival, and migration of endothelial cells
that the downregulation of TSP-1 expression by RasV12 is a(Ferrara, 2002). It has been demonstrated that expression of
critical step in the acquisition of tumor angiogenicity (Watnickoncogenic Ras results in the upregulation of VEGF (Arbiser et
et al., 2003). Our present finding that Ras-mediated CXCL-8al., 1997; Rak et al., 1995). The signaling mechanisms underlying
upregulation is necessary for tumor angiogenesis points to anthis response appear to be cell type-specific and involve the
additional mechanism through which Ras activation can triggerPI3K-pathway, the Raf/MAPK-cascade, hypoxia-inducible fac-
neovascularization. Thus, overall, the angiogenic phenotypetor 1 (HIF-1) and/or several other possible mechanisms (Rak et
al., 2000; Rak and Yu, 2004; Sodhi et al., 2001). In addition, elicited by oncogenic Ras likely depends on multiple signaling
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events that act in concert to alter the balance between pro- the concentration of oncogenic Ras. Thus, while an appreciable
and antiangiogenic factors. increase in CXCL-8 production is detected in cells expressing
In recent years, there has been growing appreciation for the near physiological levels of Ras, this response is significantly
potential role of tumor inflammation in the initiation of angiogen- enhanced at supraphysiological levels. Since amplification of
esis. In malignant human melanomas, a close correlation has activated alleles of Ras genes has been shown to occur during
been observed between tumor-associated macrophage infiltra- progression of certain human malignancies (Thor et al., 1986;
tion and microvessel density (Ono et al., 1999). In a transgenic Suhardja et al., 2001; Heidenblad et al., 2002), the aggressive
mouse model of squamous epithelial carcinogenesis, stromal nature of these tumors might be dictated, at least in part, by
infiltration of mast cells has been causally linked to the activation the high levels of CXCL-8 expression.
of angiogenesis (Coussens et al., 1999), and mast cell-deficient We have found that full stimulation of CXCL-8 transcription
KITW/ KITWv mice were shown to have decreased tumor-associ- by Ras requires the activation of both the ERK/MAPK pathway
ated vascularization (Starkey et al., 1988). The angiogenic effect and PI-3 kinase. However, activation of the ERK cascade alone
of the inflammatory cells has been attributed to their capacity was sufficient to induce a partial response. Consistent with
to induce proangiogenic factors. For example, the macrophage- this observation, Raf activation was found to induce CXCL-8
derived cytokine TNF- can upregulate the expression of bFGF expression in a global gene expression analysis using MCF-
and VEGF, and IL-4, which is secreted by activated T lympho- 10A cells (Schulze et al., 2001). Activating mutations of BRaf
cytes, basophils, and mast cells, has morphogenic and mito- are found with high frequency in human melanomas, and, in
genic activity toward vascular endothelial cells (Klein et al., 1993; metastatic lesions, the presence of constitutively active BRaf
Ryuto et al., 1996). In addition, the induction of angiogenesis is associated with poor prognosis (Houben et al., 2004). Notably,
by inflammation has been functionally linked to the secretion melanoma growth and metastasis is enhanced by tumor-
of inflammatory cell-derived proteases, which leads to the re- derived CXCL-8 expression (Bar-Eli, 1999). Although the func-
modeling of the extracellular matrix and the subsequent release tional relevance of BRaf activation for CXCL-8 expression in
of sequestered angiogenic factors (Coussens and Werb, 2002). human melanoma remains to be determined, the plausible
In support of this concept, a study employing a transgenic cause-and-effect relationships between these two events sug-
mouse model for islet cell carcinoma has demonstrated that gests that deregulated activity of Ras effector pathways may
the secretion of MMP-9 by tumor infiltrating inflammatory cells contribute to tumor progression through the upregulation of
leads to the proteolytic mobilization of VEGF (Bergers et al., CXCL-8.
2000). Furthermore, experimentally induced squamous carcino- Xenograft studies in immunocompromised nude mice have
genesis is dependent on MMP-9 expressed by inflammatory been used extensively to analyze cellular and molecular mecha-
cells (Coussens et al., 2000). nisms of tumor angiogenesis. In the present study, we have
In contrast to progress made in understanding the functional utilized this experimental system to gain insight into the role
relationship between tumor inflammation and angiogenesis, the of CXCL-8 in mediating Ras-induced tumorigenesis. Although
signals that elicit tumor-associated inflammatory responses re- nude mice are compromised in acquired immune responses
main largely unidentified. CXCL-8 is a potent chemotactic factor due to the lack of mature T lymphocytes, innate immunity in
for neutrophils and, as such, is intimately associated with the these animals is largely intact. Since CXCL-8 primarily targets
initiation of an inflammatory response (Matsushima et al., 1988; neutrophils, which act as initiators of acute inflammatory re-
Mukaida et al., 1998). Therefore, the induction of CXCL-8 by sponses, the nude mouse provides an adequate context to
oncogenic Ras could provide a mechanism by which neoplastic analyze the significance of Ras-induced CXCL-8 expression
cells recruit immune cells to the tumor site to facilitate angiogen- in tumor inflammation and angiogenesis. Nevertheless, future
esis. This idea is supported by the functional relationship that studies using mouse models that more closely recapitulate the
we observe between CXCL-8-dependent tumor infiltration by in vivo progression of spontaneously arising human tumors will
inflammatory cells and the recruitment of endothelial cells. It be instrumental in strengthening the implications of our observa-
should be noted that CXCL-8 might also contribute to the proan- tions for the pathogenic mechanism of cancer development.
giogenic effects of oncogenic Ras through its ability to directly
stimulate endothelial cell proliferation and chemotaxis (Koch et Experimental procedures
al., 1992). Therefore, CXCL-8 secretion by tumor cells express-
Cell cultureing oncogenic Ras can be exploited in diverse ways to elicit
HeLa and H125 cells were maintained in Dulbeccos’ modified Eagle mediumangiogenic responses.
(DMEM) supplemented with 10% fetal bovine serum (FBS) (Gibco BRL).Clinical studies have demonstrated that CXCL-8 is upregu-
MCF10A cells were grown in Ham’s nutrient F12/DMEM (1:1) containing 5%lated in several human malignancies, including breast cancer
horse serum, 10 g/ml insulin, 20 ng/ml EGF, 5 g/ml hydrocortisone, and
(Yokoe et al., 1997), colon cancer (Cuenca et al., 1992), pancre- 100 ng/ml cholera toxin. All cells were cultured at 37
C in the presence of
atic cancer (Le et al., 2000), melanoma (Nurnberg et al., 1999; 5% CO2. To generate Tet-Off stable cell lines, tetracycline-transactivator
Singh et al., 1999), and non-small cell lung cancer (NSCLC) (tTA)-transgenic HeLa cells (Clonetech) were cotransfected with a hygro-
mycin-resistance marker and a plasmid encoding the constitutively active(Smith et al., 1994). Generally, CXCL-8 production is linked with
mutant (12G→V) of HA-epitope tagged H-RasV12 under a tetracycline-tumor vascularization, metastatic phenotype, and overall poor
responsive promoter (pTRE-H-RasV12) and selected with 200 g/ml hygro-prognosis (Ueda et al., 1994; Kitadai et al., 1998; Nurnberg et
mycin for two weeks. Resistant clones were isolated and tested for tetracy-al., 1999; Singh et al., 1999). Moreover, the tumorigenic potential
cline-responsive expression of the transgene.
of human colon, pancreatic, and prostate cancer cells has been
shown to directly correlate with the amount of CXCL-8 expres- Western blot analysis
sion (Shi et al., 1999; Inoue et al., 2000; Li et al., 2001). We Cells were lysed and protein concentrations of cell lysates were determined
by Coomassie protein assay (Pierce). Samples were separated on 12.5%have found that the extent of CXCL-8 induction depends on
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SDS-polyacrylamide gels and electrophoretically transferred to nitrocellulose Control animals received an identical dose of rat IgG2b control antibody
membranes (Schleicher & Schuell). Blots were incubated with the following (clone A95-A, BD Biosciences).
antibodies: Ras-specific rabbit polyclonal, HA-epitope specific mouse
monoclonal (12CA5), or tubulin-specific mouse monoclonal (Sigma). Immune Tumor morphological and histochemical examination
complexes were visualized by incubation with either a goat anti-rabbit or a For immunohistochemical staining, formalin-fixed or snap-frozen fragments
goat anti-mouse HRP-conjugated secondary antibody (Cappel). The immu- of tumor specimens were sectioned to 5 m thickness. Paraffin-embedded
noreactive band was visualized by enhanced chemiluminescence (Perkin- sections were deparrafinized and rehydrated. Primary antibodies were added
Elmer). in the following dilutions: anti-PCNA 1:100 (Santa Cruz), anti-MIntegrin 1:100
(Santa Cruz), anti-CD31 1:50 (BD Biosciences). The sections were incubated
RNA isolation and reverse transcription (RT)-PCR analysis overnight at 4
C, after which the appropriate biotinylated secondary antibody
Total RNA was prepared using the RNeasy RNA isolation kit (Qiagen). cDNA (Vector Laboratories) was added. Following secondary antibody incubation,
was synthesized from 2.5 g of total RNA using an Oligo-dT primer (In- the VectaStain Elite ABC Reagent (Vector Laboratories) was applied, and
vitrogen) in a 20 l reaction. 2l of cDNA was then used to amplify the human the subsequent antibody/enzyme conjugate was developed with DAB. All
CXCL-8 sequence, the transgene-specific sequence of HA-H-RasV12 and sections were counterstained with hematoxylin. Hematoxylin and eosin
HA-K-RasV12, the partial sequence of human CXCR-1 and -2, two splice staining was performed separately by the University Histology Services
variants of human VEGF-A, or human thrombospondin using specific PCR (SUNY Stony Brook).
primers (see Supplemental Data at http://www.cancercell.org/cgi/content/
full/6/4/447/DC1/). The conditions for all PCR reactions were: 3 min at 94
C, Quantitation of tumor composition and vascular density
followed by 1 min at 95
C, 1 min at 55
C, 1 min at 72
C for 25 cycles, and Sections from peripheral and central regions of a tumor were imaged at low
then 1 cycle of 10 min at 72
C. PCR amplification of the 1007 bp sequence magnification (2.5	), and areas of viable tumor tissue and necrosis were
of human GAPDH was used to control the quality of the cDNA. evaluated using the Zeiss Axiovision software program. Blood vessel density
was quantified by counting the total number of CD31-positive vessels across
ELISA assay the whole section of tumors. The diameter of blood vessels was calculated
Tissue culture supernatants or serum were analyzed in duplicate using hu- with the Zeiss Axiovision software program. For these analyses, six different
man CXCL-8 specific ELISA purchased from R&D Systems. tumor samples were evaluated per experimental condition.
Adenoviral infection Flow cytometry
Replication-deficient recombinant adenovirus (Ad5E1) driving expression HTO cells were induced for transgene expression 24 hr prior to the experi-
of either -galactosidase, HA-H-RasV12, or HA-K-RasV12 was produced in ment. Cells were incubated with FITC-conjugated monoclonal antibodies to
293 cells. Target cells were infected with 500 recombinant viral particles CXCR-1 or CXCR-2 (BD Biosciences) or FITC-labeled matched mouse IgG
per cell. To assess adenoviral infection efficiency, cells infected with the isotype (Rockland) as a control for 2 hr at 4
C. Fluorescence was measured
Ad--galactosidase construct were fixed 24 hr after infection with 0.5% in a Becton Dickinson FACScalibur.
glutaraldehyde in PBS for 15 min and subsequently stained with X-Gal at
37
C to detect -galactosidase-positive cells. Reagents and mammalian expression plasmids
The following pharmacological inhibitors at indicated working concentrations
Luciferase and -galactosidase assay were employed in our studies: 10 M MEK inhibitor U0126 (CalBiochem);
HeLa cells were plated at a density of 5 	 104 cells per well in a 24-well- 20 M PI3K inhibitor LY 294002 (CalBiochem). Recombinant human CXCL-8
plate. Luciferase-reporter plasmid (250 ng/well) was cotransfected with Tk- was purchased from R&D Systems. pCGT was used as a mammalian expres-
-galactosidase (250 ng/well) plus effector plasmids (500 ng/well) using the sion vector to express RasV12, RafCAAX, RacV12, and RacN17. The follow-
FuGene 6 transfection Reagent (Roche). Empty vector (PCGT) was used to ing constructs were generously provided: MKK7-JNK1 by Dr. Roger Davis
equalize the total amount of transfected DNA in all samples. Luciferase (University of Massachusetts, Worcester), myr-Akt by Dr. Nissim Hay (Univer-
activities were measured 24 hr after transfection and normalized to sity of Chicago), p110CAAX by Dr. Julian Downward (London Research
-galactosidase activities. Results are represented as mean values and SD Institute), pCMV4-IBS32A/S36A by Dr. Nancy Reich (SUNY Stony Brook),
from three independent experiments. Activity achieved by RasV12-expres- and the CXCL-8 luciferase reporter construct by Dr. Erich Mackow (SUNY
sion is arbitrarily set as 100%. Stony Brook).
In vivo tumor formation assays Statistical analysis
Studies were conducted in eight-week-old immunocompromised athymic Statistical significance for in vivo experiments was determined by one-way
male mice (NIH Swiss Nude, Taconic Farms). 1	 106 cells were resuspended analysis of variance (ANOVA) with the Tukey-Kramer multiple-comparison
in 150 l sterile PBS and injected subcutaneously with a 26-gauge needle post-test (GraphPad Instat, GraphPad Software Inc.). Comparison between
into the flank of anaesthetized animals. Tumor size was monitored every two groups was made using Student’s t test for unpaired data when appro-
two days using calipers, and the length (l) and width (w) of the developing priate. In all analysis, p  0.05 was considered statistically significant.
tumor was converted to volume using the equation (w2 	 l)/2. Mice were
sacrificed when tumors reached a maximum size of 2 cm in the largest
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